GoodReid Investment Counsel
Latest Top Picks
Look for companies that are the future. The US has the most expensive healthcare as a percentage of GDP by a long shot. They have to get a handle on this, and one way is through a phone or video format. This company is a bit too risky, because they are focused on just this issue. He prefers CVS with their distribution network.
Look for companies that are the future. The US has the most expensive healthcare as a percentage of GDP by a long shot. They have to get a handle on this, and one way is through a phone or video format. This company is a bit too risky, because they are focused on just this issue. He prefers CVS with their distribution network.
PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
ABBV vs. PFE Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.
(A Top Pick Aug 22/19, Down 10%) Their product that competes with Zoom has done well. The rest of the business is shaky. It's a timing issue. Well positioned for the next 10 years. Not expensive. He'd be a buyer and a holder.
(A Top Pick Aug 22/19, Down 10%) Their product that competes with Zoom has done well. The rest of the business is shaky. It's a timing issue. Well positioned for the next 10 years. Not expensive. He'd be a buyer and a holder.
Has done extremely well on both organic growth and on the market's re-rating. Will be beneficiaries as we move more to plastic in the post-pandemic world. Trading at a high 30s multiple, a bit extreme. Fewer opportunities and more risk in the face of Square, PayPal, and the like.
